Key Highlights
- iShares U.S. Medical Devices ETF (NYSEARCA:IHI) investors saw diagnostics deal flow on Monday, October 19, 2026, when Hologic signed a definitive agreement to acquire Reveal Genomics, as reported.
- Reveal Genomics develops HER2DX, a genomic test for HER2-positive breast cancer. The price and expected closing date were not captured in the reporting used here, so the deal size is unknown.
- Hologic agreed in October 2025 to be taken private by Blackstone (NYSE:BX) and TPG (NASDAQ:TPG) for up to USD 79 per share, an enterprise value of up to USD 18.3 billion.
- Whether that buyout has closed was not confirmed for this article, so Hologic is not tagged with a listing, and the read-across to listed device makers is indirect.
What Hologic Agreed to Buy
iShares U.S. Medical Devices ETF (NYSEARCA:IHI) holds US makers of medical equipment and diagnostics, a group in which takeovers often set valuation markers. On Monday, October 19, 2026, Hologic signed a definitive agreement to acquire Reveal Genomics, according to a report aggregated by Ground News. Reveal Genomics, based in Barcelona, develops HER2DX, a test that analyses tumour genes to guide treatment of HER2-positive breast cancer. Hologic is best known for breast imaging and women's health diagnostics. The purchase price and timetable were not captured here. Separately, Hologic agreed in October 2025 to be acquired by Blackstone and TPG for USD 76 per share in cash plus a contingent value right worth up to USD 3.
Why Genomic Tests Extend a Breast Health Franchise
A breast health business can earn revenue at several steps: screening with mammography, biopsy to confirm disease and then tests that predict how a tumour will behave. Hologic already moved into that last step when it bought Biotheranostics in 2021, a cancer molecular diagnostics firm. Adding HER2DX would extend that reach to treatment decisions in HER2-positive cancer, a subtype with a distinct set of targeted drugs. For iShares U.S. Medical Devices ETF (NYSEARCA:IHI), the read-across is that large device and diagnostics groups continue to buy specialised tests rather than build them. The contingent value right in Hologic's own buyout is tied to Breast Health revenue goals, which suggests why breast cancer assets are a priority, an inference.
Risks and What to Watch
The first risk is information: without a disclosed price, investors cannot judge what Hologic paid or compare it with listed peers. The second risk is reimbursement, because a genomic test earns revenue only when insurers and health systems agree to pay for it, which can take years in each market. The third risk is regulatory, as tests used in treatment decisions often need approval or clearance in each region where they are sold. For iShares U.S. Medical Devices ETF (NYSEARCA:IHI), the risk is that one private-company deal says little about listed valuations. Investors should watch for deal terms, closing details and the Fed decision on Wednesday, October 28.
Where Things Stand
The answer is that the Reveal Genomics agreement touches iShares U.S. Medical Devices ETF (NYSEARCA:IHI) only indirectly, as a sign that diagnostics groups are still buying cancer tests. The deal adds HER2DX to a breast health franchise that already includes screening and biopsy tools. Its size remains undisclosed in the reporting used here. The next catalysts are any filing of terms, closing conditions and the Fed meeting on October 27 to 28. Undisclosed deal values cannot be assessed, and this is not investment advice.






Please wait processing your request...